• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于预测 CYP3A 代谢药物在孕妇体内处置的 PBPK 模型:验证和辨别 CYP3A 诱导的部位。

A PBPK Model to Predict Disposition of CYP3A-Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A Induction.

机构信息

1] Department of Pharmaceutics, University of Washington, Seattle, Washington, USA [2] Department of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.

出版信息

CPT Pharmacometrics Syst Pharmacol. 2012 Sep 26;1(9):e3. doi: 10.1038/psp.2012.2.

DOI:10.1038/psp.2012.2
PMID:23835883
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3606941/
Abstract

Besides logistical and ethical concerns, evaluation of safety and efficacy of medications in pregnant women is complicated by marked changes in pharmacokinetics (PK) of drugs. For example, CYP3A activity is induced during the third trimester (T3). We explored whether a previously published physiologically based pharmacokinetic (PBPK) model could quantitatively predict PK profiles of CYP3A-metabolized drugs during T3, and discern the site of CYP3A induction (i.e., liver, intestine, or both). The model accounted for gestational age-dependent changes in maternal physiological function and hepatic CYP3A activity. For model verification, mean plasma area under the curve (AUC), peak plasma concentration (Cmax), and trough plasma concentration (Cmin) of midazolam (MDZ), nifedipine (NIF), and indinavir (IDV) were predicted and compared with published studies. The PBPK model successfully predicted MDZ, NIF, and IDV disposition during T3. A sensitivity analysis suggested that CYP3A induction in T3 is most likely hepatic and not intestinal. Our PBPK model is a useful tool to evaluate different dosing regimens during T3 for drugs cleared primarily via CYP3A metabolism.CPT: Pharmacometrics & Systems Pharmacology (2012) 1, e3; doi:10.1038/psp.2012.2; advance online publication 26 September 2012.

摘要

除了后勤和伦理方面的考虑外,评估孕妇用药的安全性和疗效还因药物药代动力学(PK)的显著变化而变得复杂。例如,CYP3A 活性在妊娠晚期(T3)期间被诱导。我们探讨了之前发表的基于生理学的药代动力学(PBPK)模型是否可以定量预测 T3 期间 CYP3A 代谢药物的 PK 曲线,并辨别 CYP3A 诱导的部位(即肝脏、肠道或两者兼有)。该模型考虑了母体生理功能和肝 CYP3A 活性随妊娠年龄的变化。为了模型验证,预测并比较了咪达唑仑(MDZ)、硝苯地平(NIF)和茚地那韦(IDV)的平均血浆曲线下面积(AUC)、血浆峰浓度(Cmax)和血浆谷浓度(Cmin),并与已发表的研究进行了比较。PBPK 模型成功预测了 T3 期间 MDZ、NIF 和 IDV 的处置。敏感性分析表明,T3 期间 CYP3A 的诱导最有可能是肝脏而非肠道。我们的 PBPK 模型是评估 T3 期间主要通过 CYP3A 代谢清除的药物的不同给药方案的有用工具。CPT:药物代谢动力学与系统药理学(2012 年)1,e3;doi:10.1038/psp.2012.2;2012 年 9 月 26 日在线提前发布。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c2/3606941/a33315582313/psp20122f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c2/3606941/1a955e229d20/psp20122f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c2/3606941/708d53abfc9e/psp20122f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c2/3606941/b80ece9e51cb/psp20122f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c2/3606941/3bbd2236a689/psp20122f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c2/3606941/a33315582313/psp20122f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c2/3606941/1a955e229d20/psp20122f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c2/3606941/708d53abfc9e/psp20122f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c2/3606941/b80ece9e51cb/psp20122f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c2/3606941/3bbd2236a689/psp20122f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c2/3606941/a33315582313/psp20122f5.jpg

相似文献

1
A PBPK Model to Predict Disposition of CYP3A-Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A Induction.用于预测 CYP3A 代谢药物在孕妇体内处置的 PBPK 模型:验证和辨别 CYP3A 诱导的部位。
CPT Pharmacometrics Syst Pharmacol. 2012 Sep 26;1(9):e3. doi: 10.1038/psp.2012.2.
2
A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women.建立生理基于药代动力学模型预测 CYP2D6 和 CYP1A2 代谢药物在孕妇体内的处置。
Drug Metab Dispos. 2013 Apr;41(4):801-13. doi: 10.1124/dmd.112.050161. Epub 2013 Jan 25.
3
Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19.扩展一个生理药代动力学(PBPK)模型,以预测通过多种细胞色素P450(CYP)酶(包括CYP2B6、CYP2C9和CYP2C19)清除的药物在孕妇体内的处置情况。
Br J Clin Pharmacol. 2014 Mar;77(3):554-70. doi: 10.1111/bcp.12207.
4
Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates.基于生理学的预测:抑制肠道和肝脏代谢对 CYP3A 底物在人体内药代动力学的影响。
J Pharm Sci. 2010 Jan;99(1):486-514. doi: 10.1002/jps.21802.
5
A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions.涉及肠和肝的基于机制的生理药代动力学-酶周转模型,用于预测 CYP3A 诱导介导的药物相互作用。
J Pharm Sci. 2013 Aug;102(8):2819-36. doi: 10.1002/jps.23613. Epub 2013 Jun 11.
6
A Semi-Mechanistic Metabolism Model of CYP3A Substrates in Pregnancy: Predicting Changes in Midazolam and Nifedipine Pharmacokinetics.妊娠 CYP3A 底物的半机械代谢模型:预测咪达唑仑和硝苯地平药代动力学的变化。
CPT Pharmacometrics Syst Pharmacol. 2012 Sep 26;1(9):e2. doi: 10.1038/psp.2012.5.
7
Application of a "Fit for Purpose" PBPK Model to Investigate the CYP3A4 Induction Potential of Enzalutamide.应用“适用目的”的生理药代动力学(PBPK)模型研究恩杂鲁胺的CYP3A4诱导潜力。
Drug Metab Lett. 2016;10(3):172-179. doi: 10.2174/1872312810666160729124745.
8
A simplified PBPK modeling approach for prediction of pharmacokinetics of four primarily renally excreted and CYP3A metabolized compounds during pregnancy.一种简化的 PBPK 建模方法,用于预测妊娠期间四种主要经肾排泄和 CYP3A 代谢的化合物的药代动力学。
AAPS J. 2013 Oct;15(4):1012-24. doi: 10.1208/s12248-013-9505-3. Epub 2013 Jul 9.
9
Prediction of gestational age-dependent induction of in vivo hepatic CYP3A activity based on HepaRG cells and human hepatocytes.基于HepaRG细胞和人肝细胞预测体内肝脏CYP3A活性的孕龄依赖性诱导
Drug Metab Dispos. 2015 Jun;43(6):836-42. doi: 10.1124/dmd.114.062984. Epub 2015 Mar 23.
10
A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4.用于代谢 CYP1A2、CYP2D6 和 CYP3A4 药物的妊娠生理基于药代动力学(p-PBPK)模型。
Br J Clin Pharmacol. 2012 Nov;74(5):873-85. doi: 10.1111/j.1365-2125.2012.04363.x.

引用本文的文献

1
A close examination of BCRP's role in lactation and methods for predicting drug distribution into milk.对乳腺癌耐药蛋白(BCRP)在哺乳期的作用及预测药物向乳汁中分布的方法进行深入研究。
CPT Pharmacometrics Syst Pharmacol. 2024 Nov;13(11):1856-1869. doi: 10.1002/psp4.13243. Epub 2024 Sep 18.
2
The impact of pregnancy and associated hormones on the pharmacokinetics of Δ-tetrahydrocannabinol.妊娠及相关激素对Δ-四氢大麻酚药代动力学的影响。
Expert Opin Drug Metab Toxicol. 2024 Jan-Feb;20(1-2):73-93. doi: 10.1080/17425255.2024.2309213. Epub 2024 Mar 4.
3
Animal-free assessment of developmental toxicity: Combining PBPK modeling with the ReproTracker assay.

本文引用的文献

1
A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4.用于代谢 CYP1A2、CYP2D6 和 CYP3A4 药物的妊娠生理基于药代动力学(p-PBPK)模型。
Br J Clin Pharmacol. 2012 Nov;74(5):873-85. doi: 10.1111/j.1365-2125.2012.04363.x.
2
Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling.正常妊娠期间与妊娠龄相关的解剖学、生理学和代谢变化:用于生理基于药代动力学建模的所需参数的数据库。
Clin Pharmacokinet. 2012 Jun 1;51(6):365-96. doi: 10.2165/11597440-000000000-00000.
3
无动物评估发育毒性:结合 PBPK 模型与 ReproTracker 检测。
Toxicology. 2023 Dec;500:153684. doi: 10.1016/j.tox.2023.153684. Epub 2023 Nov 27.
4
Pregnancy related hormones increase CYP3A mediated buprenorphine metabolism in human hepatocytes: a comparison to CYP3A substrates nifedipine and midazolam.妊娠相关激素可增加人肝细胞中细胞色素P450 3A(CYP3A)介导的丁丙诺啡代谢:与CYP3A底物硝苯地平和咪达唑仑的比较。
Front Pharmacol. 2023 Jul 5;14:1218703. doi: 10.3389/fphar.2023.1218703. eCollection 2023.
5
The MPRINT Hub Data, Model, Knowledge and Research Coordination Center: Bridging the gap in maternal-pediatric therapeutics research through data integration and pharmacometrics.MPRINT 中心数据、模型、知识和研究协调中心:通过数据集成和药物动力学研究弥合母婴治疗学研究的差距。
Pharmacotherapy. 2023 May;43(5):391-402. doi: 10.1002/phar.2765. Epub 2023 Jan 25.
6
Predicting Human Fetal Drug Exposure Through Maternal-Fetal PBPK Modeling and In Vitro or Ex Vivo Studies.通过母体-胎儿 PBPK 模型和体外或离体研究预测人类胎儿药物暴露。
J Clin Pharmacol. 2022 Sep;62 Suppl 1(Suppl 1):S94-S114. doi: 10.1002/jcph.2117.
7
Pharmacokinetics of the most commonly used antihypertensive drugs throughout pregnancy methyldopa, labetalol, and nifedipine: a systematic review.妊娠期最常用的降压药物(甲基多巴、拉贝洛尔和硝苯地平)的药代动力学:系统评价。
Eur J Clin Pharmacol. 2022 Nov;78(11):1763-1776. doi: 10.1007/s00228-022-03382-3. Epub 2022 Sep 15.
8
Prediction of Maternal and Fetal Doravirine Exposure by Integrating Physiologically Based Pharmacokinetic Modeling and Human Placenta Perfusion Experiments.整合生理药代动力学模型和人胎盘灌注实验预测地瑞那韦在母体和胎儿的暴露量。
Clin Pharmacokinet. 2022 Aug;61(8):1129-1141. doi: 10.1007/s40262-022-01127-0. Epub 2022 May 17.
9
Applications, Challenges, and Outlook for PBPK Modeling and Simulation: A Regulatory, Industrial and Academic Perspective.基于生理药代动力学建模和模拟的应用、挑战与展望:监管、工业和学术视角。
Pharm Res. 2022 Aug;39(8):1701-1731. doi: 10.1007/s11095-022-03274-2. Epub 2022 May 13.
10
Physiologically-based pharmacokinetic simulations in pharmacotherapy: selection of the optimal administration route for exogenous melatonin.药物治疗中基于生理的药代动力学模拟:外源性褪黑素最佳给药途径的选择。
ADMET DMPK. 2019 Feb 23;7(1):44-59. doi: 10.5599/admet.625. eCollection 2019.
Physiologically-based pharmacokinetic (PBPK) models for assessing the kinetics of xenobiotics during pregnancy: achievements and shortcomings.
用于评估妊娠期间外来化合物动力学的基于生理的药代动力学 (PBPK) 模型:成就与不足。
Curr Drug Metab. 2012 Jul;13(6):695-720. doi: 10.2174/138920012800840374.
4
Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir.HIV 蛋白酶抑制剂的复杂药物相互作用 2:利托那韦或奈非那韦诱导细胞色素 P450 1A2、2B6 和 2C9 的体内诱导和体外与体内相关性。
Drug Metab Dispos. 2011 Dec;39(12):2329-37. doi: 10.1124/dmd.111.038646. Epub 2011 Sep 19.
5
Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction.基于生理学的高肠道提取率 CYP3A 底物肠首过代谢的药代动力学模型。
Drug Metab Dispos. 2011 Sep;39(9):1633-42. doi: 10.1124/dmd.111.039248. Epub 2011 Jun 1.
6
Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir.HIV 蛋白酶抑制剂 1 的复杂药物相互作用:利托那韦或奈非那韦对细胞色素 P4503A 的失活、诱导和抑制。
Drug Metab Dispos. 2011 Jun;39(6):1070-8. doi: 10.1124/dmd.110.037523. Epub 2011 Mar 15.
7
Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review.在监管审查期间,生理基于药代动力学(PBPK)建模和模拟的应用。
Clin Pharmacol Ther. 2011 Feb;89(2):259-67. doi: 10.1038/clpt.2010.298. Epub 2010 Dec 29.
8
Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.代谢与转运在决定口服药物吸收和肠道壁代谢中的相互作用:应用“先进的溶解、吸收、代谢(ADAM)”模型进行的模拟评估。
Curr Drug Metab. 2010 Nov;11(9):716-29. doi: 10.2174/138920010794328913.
9
Physiologically-based pharmacokinetics in drug development and regulatory science.生理药代动力学在药物研发和监管科学中的应用。
Annu Rev Pharmacol Toxicol. 2011;51:45-73. doi: 10.1146/annurev-pharmtox-010510-100540.
10
Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data.基于体外清除率和通透性数据预测 25 种 CYP3A 底物的人体肠道首过代谢。
Drug Metab Dispos. 2010 Jul;38(7):1147-58. doi: 10.1124/dmd.110.032649. Epub 2010 Apr 5.